Interstitial lung disease associated with nanoparticle albumin-bound paclitaxel treatment in patients with lung cancer

Kashiwada, Takeru; Saito, Yoshinobu; Terasaki, Yasuhiro; Hisakane, Kakeru; Takeuchi, Susumu; Sugano, Teppei; Miyanaga, Akihiko; Noro, Rintaro; Minegishi, Yuji; Seike, Masahiro; Kubota, Keiichi; Gemma, Akihiko

doi:10.1093/jjco/hyy180

Cited by 18 publications

(26 citation statements)

References 28 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Several studies have demonstrated that pre-existing ILD confers an increased risk for the development of interstitial pneumonitis associated with taxane therapy. 5,7 In a small prospective trial of NSCLC patients with pre-existing pulmonary fibrosis treated with combination paclitaxel and carboplatin, the rate of grade 3 or higher pneumonitis was 27% and, as a result, the authors concluded that paclitaxel therapy should be avoided in patients with pre-existing pulmonary fibrosis. 16 New research, however, has suggested that the newer taxane formulation, nab-paclitaxel, can be safely administered to patients with pre-existing ILD.…”

Section: Risk Factorsmentioning

confidence: 99%

“…5,21 Computed tomography (CT) scan commonly shows diffuse ground-glass opacities (GGO). 5,7,15,26 Reticular opacities, thickened septal lines and irregular airspace consolidations consistent with non-specific interstitial pneumonitis (NSIP) or organizing pneumonia (OP) have also been described. 5,8,15 Some patients also present with diffuse GGO, consolidations and traction bronchiectasis consistent with diffuse alveolar damage.…”

Section: Radiographic and Histologic Featuresmentioning

confidence: 99%

“…5,8,15 Some patients also present with diffuse GGO, consolidations and traction bronchiectasis consistent with diffuse alveolar damage. 7 Lung biopsy is not usually necessary to establish a diagnosis of taxane-induced pneumonitis; however, several case reports have described the pathological findings of patients presenting with severe taxane-induced pneumonitis. Wong et al 26 reported a case of a patient with stage IIIb breast cancer treated with paclitaxel who developed taxane-induced pneumonitis.…”

Section: Radiographic and Histologic Featuresmentioning

confidence: 99%

See 2 more Smart Citations

Pulmonary toxicity of systemic lung cancer therapy

Long

Suresh

2020

Respirology

View full text Add to dashboard Cite

Lung cancer is the leading cause of cancer-related deaths worldwide. As new therapies are developed, it is important to understand the pulmonary toxicities associated with systemic lung cancer therapies. Cytotoxic chemotherapy regimens for NSCLC often include taxanes. Pulmonary toxicity from taxanes presents as an ILD-type reaction characterized by increasing dyspnoea, dry cough, fever and bilateral pulmonary interstitial infiltrates. The incidence of taxane-induced pneumonitis is rare, and many patients respond to steroid therapy; however, fatal cases have been reported. Patients with NSCLC are routinely tested for the presence of tumour oncogenes to determine their candidacy for targeted therapies, such as TKI. EGFR-TKI can cause pneumonitis characterized by progressive dyspnoea and hypoxia. EGFR-TKIassociated ILD rarely presents as an AIP with rapidly progressive respiratory failure and high mortality rates. The most recent development in lung cancer therapy has been the discovery of immune checkpoint inhibitor (ICI). ICI pneumonitis has been increasingly recognized as a common complication of ICI therapy, with reported incidence as high as 19% in some clinical settings. Early-grade ICI pneumonitis may be asymptomatic; however, high-grade ICI pneumonitis can result in progressive dyspnoea, hypoxia and respiratory failure. ICI pneumonitis is unique in that only half of the patients will improve with steroid treatment, and mortality rates are high. As treatment of NSCLC evolves, providers must be able to recognize and respond to the development of drug-induced pulmonary toxicities.

show abstract

Section: Risk Factorsmentioning

confidence: 99%

Section: Radiographic and Histologic Featuresmentioning

confidence: 99%

Section: Radiographic and Histologic Featuresmentioning

confidence: 99%

See 1 more Smart Citation

Pulmonary toxicity of systemic lung cancer therapy

Long

Suresh

2020

Respirology

View full text Add to dashboard Cite

show abstract

“…Considering the high frequency of ICI-related lung injury for patients with ILD, cytotoxic drugs seem to be an optimal treatment for such patients. However, most cases of ICI-related lung injury have been manageable ( 8 ), while cytotoxic agent-related lung injury often leads to severe and potentially fatal adverse events in patients with pre-ILD ( 24 ). In addition, some cases with pre-ILD, including Case 5 in the present study, experienced a good response to ICIs over a long period without ICI-related lung injury ( 25 ).…”

Section: Discussionmentioning

confidence: 99%

Pembrolizumab for Previously Untreated Patients with Advanced Non-small-cell Lung Cancer and Preexisting Interstitial Lung Disease

et al. 2020

View full text Add to dashboard Cite

Objective Pembrolizumab has beneﬁted patients with advanced non-small-cell lung cancer (NSCLC) with a programmed death-ligand (PD-L)1 high expression, but little information is available regarding its safety for patients with interstitial lung disease (ILD). The aim of this study was to assess the efficacy and tolerability of pembrolizumab for patients with advanced NSCLC and preexisting ILD. Methods We retrospectively reviewed the medical records of five patients with advanced NSCLC and preexisting ILD who received pembrolizumab monotherapy in a first-line setting. Patients All patients had mild ILD and pulmonary emphysema with a forced vital capacity within the normal range. Pembrolizumab was administered at a dose of 200 mg/body on day 1 every 3 weeks. Results The overall response rate was 60%. Four patients developed pembrolizumab-induced lung injury, which was improved in all cases by corticosteroid therapy. One patient received pembrolizumab for two years, did not experience lung injury and achieved a complete response. Conclusion Pembrolizumab has a high risk of inducing lung injury in patients with preexisting ILD, although it may be very effective in NSCLC patients with a high PD-L1 expression, even concurrent with preexisting ILD. Further large-scale studies are needed to determine risk factors of pembrolizumab-induced lung injury in such patients.

show abstract

“…Previous studies revealed that CEA possessed low sensitivity and could not appropriately present the complete potency for predicting and monitoring the clinical diagnosis and treatment in colorectal cancer [6]. In recent years, many in ammatory parameters from peripheral blood and serum have been evaluated in the diagnosis and prognosis of multiple malignancies, including colorectal cancer [7,8], such as circulating neutrophils [9], lymphocytes [10], monocytes [11], platelets [12], and albumin [13]. As crucial components of host immunity, lymphocytes can in ltrate into the tumor microenvironment, and they play a vital role in cell-mediated immunity, preventing the proliferation and metastatic activity of colorectal cancer [14].…”

Section: Introductionmentioning

confidence: 99%

Diagnostic value of the lymphocyte-to-monocyte and albumin-to-globulin ratios in patients with colon cancer

Huang¹,

Mo²,

Hu³

et al. 2020

Preprint

View full text Add to dashboard Cite

Background: Ample evidence has revealed that the lymphocyte-to-monocyte ratio (LMR) and albumin-to-globulin ratio (AGR) are cancer-related inflammatory markers. The present study aimed to assess whether LMR and AGR, alone or in combination with carcinoembryonic antigen (CEA), was a useful diagnostic marker for colon cancer.Methods: This retrospective study enrolled 251 patients with colon cancer, 171 patients with benign colon diseases, and 187 healthy control subjects from January 2012 to September 2019. Mann-Whitney U test or Chi-square test were used to analyze differences between groups in laboratory parameters and clinicopathological features. The diagnostic value of LMR and AGR combined or not with CEA in colon cancer patients was determined via a receiver operating characteristic (ROC) curve.Results: The levels of LMR and AGR were decreased in the colon cancer group compared with the healthy control and benign colon disease groups. The LMR and AGR were correlated with lymph node metastasis, tumor size, and clinical stage. Moreover, AGR was associated with distant metastasis. Both the LMR (r = −0.137, p = 0.030) and AGR (r = −0.178, p = 0.005) were negatively correlated with the concentration of CEA. LMR or AGR combined with CEA could enhance sensitivity (75.30% for LMR + CEA, 58.57% for AGR + CEA) and generate larger area under curve (AUC; 0.75 for LMR + CEA, 0.74 for AGR + CEA) compared with the LMR (p < 0.001), AGR (p < 0.001), or CEA (p < 0.001) alone.Conclusion: The combination of LMR or AGR with CEA may enhance the sensitivity and diagnostic efficacy of detecting colon cancer from benign colon diseases.

show abstract

Interstitial lung disease associated with nanoparticle albumin-bound paclitaxel treatment in patients with lung cancer

Cited by 18 publications

References 28 publications

Pulmonary toxicity of systemic lung cancer therapy

Pulmonary toxicity of systemic lung cancer therapy

Pembrolizumab for Previously Untreated Patients with Advanced Non-small-cell Lung Cancer and Preexisting Interstitial Lung Disease

Diagnostic value of the lymphocyte-to-monocyte and albumin-to-globulin ratios in patients with colon cancer

Contact Info

Product

Resources

About